Related Experiment Video
Updated: Dec 18, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.4K
Is tofacitinib a game-changing drug for ulcerative colitis?
Fernando Magro1,2,3,4, Maria Manuela Estevinho1,5
1Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal.
United European Gastroenterology Journal
|June 20, 2020
Summary
Tofacitinib offers a new treatment option for ulcerative colitis patients unresponsive to conventional therapies. This review examines its current use and future potential in managing inflammatory bowel disease.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Ulcerative colitis (UC) pathophysiology knowledge has expanded therapeutic options.
- 25-40% of UC patients are non-responders, and 10% require colectomy.
Observation:
- Janus kinase (JAK) inhibitors block cytokine signaling in inflammatory conditions.
- Tofacitinib is the first approved JAK inhibitor for moderate-to-severe UC.
- It is indicated for patients refractory to conventional or biologic therapies.
Findings:
- Review of current tofacitinib use in ulcerative colitis.
- Exploration of safety and efficacy concerns.
- Discussion of future applications and research directions.
Implications:
- Tofacitinib represents a significant advancement in UC treatment.
- Understanding its role is crucial for managing refractory disease.
- Further research may optimize JAK inhibitor therapy for inflammatory bowel disease.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
352
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
352
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
372
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
372
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
356
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
356
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
340
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
340
01:29Inflammatory Bowel Disease IV: Pharmacological Management
351
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
351
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
744
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
744